Abstract
We have measured the psychological effects of acebutolol and atenolol in sixteen patients with essential hypertension. The drugs were administered in a randomized, placebo-controlled, double-blind manner, in single daily doses of 100 mg atenolol, 400 mg acebutolol or placebo for periods of 6 weeks, each drug period being separated by a placebo period. At each 2 weekly clinic visit, a questionnaire designed for assessment of state anxiety and state arousal was administered for self-completion. Arousal was significantly reduced by atenolol over the whole 6 weeks of administration. It was not affected by acebutolol. Anxiety was significantly reduced by acebutolol but only at the first of the three 2 weekly assessments on treatment. It was not affected by atenolol. Differences in the psychological effects of these two beta-adrenoceptor blockers are discussed in terms of their lipid solubility and haemodynamic effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cruickshank J. M. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980 Aug;100(2):160–178. doi: 10.1016/0002-8703(80)90112-x. [DOI] [PubMed] [Google Scholar]
- James I. M., Griffith D. N., Pearson R. M., Newbury P. Effect of oxprenolol on stage-fright in musicians. Lancet. 1977 Nov 5;2(8045):952–954. doi: 10.1016/s0140-6736(77)90890-x. [DOI] [PubMed] [Google Scholar]
- Kayed K., Godtlibsen O. B. Central effects of the beta-adrenergic blocking agent acebutolol. A quantitative EEG study using normalised slope descriptors. Eur J Clin Pharmacol. 1977 Dec 16;12(5):327–331. doi: 10.1007/BF00562446. [DOI] [PubMed] [Google Scholar]
- Krishnan G. Oxprenolol in the treatment of examination stress. Curr Med Res Opin. 1976;4(3):241–243. doi: 10.1185/03007997609109311. [DOI] [PubMed] [Google Scholar]
- Man in 't Veld A. J., Schalekamp M. A. How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol. 1982;13(Suppl 2):245S–257S. doi: 10.1111/j.1365-2125.1982.tb01922.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thayer R. E. Measurement of activation through self-report. Psychol Rep. 1967 Apr;20(2):663–678. doi: 10.2466/pr0.1967.20.2.663. [DOI] [PubMed] [Google Scholar]